PATH, Washington, DC, USA.
PATH, Washington, DC, USA.
Vaccine. 2017 Dec 14;35(49 Pt A):6775-6782. doi: 10.1016/j.vaccine.2017.09.045. Epub 2017 Oct 4.
PATH hosted the inaugural Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC in June 2016, bringing together experts from around the world for a highly collaborative forum to discuss progress in the development of new enteric vaccines. Diarrheal disease and long-term sequelae caused by infections with the bacterial pathogens Shigella and enterotoxigenic E. coli (ETEC) pose a significant public health burden in low-income communities. There are currently no licensed vaccines against these pathogens, and the global health community has recently prioritized their development. The 2016 VASE Conference aimed to accelerate communication and progress among those working in the enteric vaccine field to make Shigella and ETEC vaccines a reality as quickly as possible. Research presented in oral and poster presentations at the VASE Conference covered a range of topics, including: the global burden of disease and public health case for Shigella and ETEC vaccines; current vaccine candidates in development; immunology and host responses to the pathogens; and the rationale for and status of combined Shigella-ETEC vaccine candidates. This article reviews key points and highlighted research presented in each of the plenary conference sessions and poster presentations at the 2016 conference. Planning for the 2018 VASE Conference is underway and will likely provide an important platform for sharing the latest updates on Shigella and ETEC vaccine research efforts and maintaining the momentum for accelerating this work. It is also expected that the VASE Conference will continue to provide a unique opportunity for those in the enteric vaccine field to share ideas, make connections, and create workable plans to make Shigella and ETEC vaccines a reality. (Updates available at: www.vaseconference.org.).
PATH 于 2016 年 6 月在华盛顿特区主办了首届志贺氏菌和肠产毒性大肠杆菌（VASE）疫苗会议，汇集了来自世界各地的专家，共同探讨开发新型肠内疫苗的进展。细菌性病原体志贺氏菌和肠产毒性大肠杆菌（ETEC）感染引起的腹泻病和长期后遗症给低收入社区带来了巨大的公共卫生负担。目前尚无针对这些病原体的许可疫苗，全球卫生界最近已将其开发列为优先事项。2016 年 VASE 会议旨在加快从事肠内疫苗领域工作的人员之间的沟通和进展，尽快使志贺氏菌和 ETEC 疫苗成为现实。在 VASE 会议上的口头和海报展示中介绍的研究涵盖了一系列主题，包括：志贺氏菌和 ETEC 疫苗的全球疾病负担和公共卫生案例；当前正在开发的疫苗候选物；对病原体的免疫学和宿主反应；以及联合志贺氏菌-ETEC 疫苗候选物的原理和现状。本文回顾了每个全体会议和 2016 年会议海报展示中介绍的要点和重点研究。2018 年 VASE 会议的计划正在进行中，预计将为分享志贺氏菌和 ETEC 疫苗研究最新进展以及保持加速这项工作的势头提供重要平台。预计 VASE 会议还将继续为肠内疫苗领域的人员提供独特的机会，分享想法，建立联系，并制定可行的计划，使志贺氏菌和 ETEC 疫苗成为现实。（更新内容可在：www.vaseconference.org 获得。）。
